logo
Poor Eating Habits: ‘Informing Is No Longer Enough'

Poor Eating Habits: ‘Informing Is No Longer Enough'

Medscape19-05-2025
The 9th edition of the 'Nourrir Liège' festival was held in mid-April, with this year's theme centred on the concept of One Health — the interconnection between human, animal, and environmental health. Among the many conferences, one session focused on the hidden costs of food, offering a platform for Axelle Hoge, PhD, associate professor and public health researcher at the University of Liège, Belgium, to examine why many Belgians struggle with poor dietary habits and to propose actionable solutions.
The following interview was conducted by MediQuality , a Medscape Network platform, after her presentation at the event.
In your view, why is it now more difficult to clearly link nutrition and health?
Today, it has become increasingly difficult for the general public, health professionals, and researchers to draw a direct connection between diet and health. This is largely due to the complexity of so-called societal diseases, which are typically multifactorial in nature. While diet clearly plays a recognized role in the development of conditions such as obesity, type 2 diabetes, cardiovascular disease, certain cancers, and osteoporosis, it is only one of many contributing factors. Genetic predisposition, physical activity, exposure to environmental pollutants, and stress also influence the onset of these diseases. This interplay of multiple causes makes the relationship between diet and health more difficult to understand and quantify — even though we know that nutrition remains a major tool for disease prevention.
Was the association between diet and health more obvious in the past?
Yes, the connection used to be more apparent. In cases of nutritional deficiency, specific clinical symptoms would develop that directly pointed to the problem. I'm thinking, for example, of kwashiorkor or scurvy. It was immediately clear that the diet was lacking in either quantity or quality. Today, the situation is much more complex.
Do you think Belgian consumers are poorly informed about nutrition?
I believe they are generally aware of the main dietary recommendations. However, putting them into practice is another matter. For instance, does the average person really know what concrete steps to take to reduce their intake of unhealthy fats? I'm not so sure.
We need to move away from the idea that everything depends on information alone. For a long time, public health campaigns operated on the assumption that people simply didn't know what was good or bad for their health. That perspective is outdated. Knowledge alone is not enough to change behaviour.
Conditions like obesity and other diet-related diseases cannot be fully explained by individual choices. Our eating habits are heavily influenced by the environment in which we live. On one hand, there's the social environment — family, friends, and coworkers influence our eating behaviour through imitation and social norms. On the other hand, the physical environment — supermarkets, restaurants, schools, and workplaces — determines what foods are available, in what quantities, and at what prices. Finally, the macro-environment plays a role: food production, processing, and distribution systems, agricultural policies, and marketing all shape our dietary choices.
Have these three influencing factors — the social, physical, and macro-level environments — evolved in recent years?
Yes, all three have changed significantly over the past few decades, and these changes clearly contribute to the current rise in multifactorial diseases. Foods high in sugar, unhealthy fats, and salt have become much more widespread. Portion sizes have increased, and ready-made meals are more accessible than ever. At the same time, we now spend less time on meals, and the availability of fast food and the intensity of food marketing have exploded. Altogether, these shifts have altered our eating habits — often not for the better.
What do we know about the measurable links between diet and mortality?
One of the most comprehensive sources is the 2017 Global Burden of Disease Study, which evaluated the health effects of diet in 195 countries. The study found that approximately one in five deaths worldwide is attributable to dietary risks. In terms of morbidity, it estimated that around 255 million years of healthy life are lost annually due to chronic diseases worsened by poor diets.
Three specific dietary factors were identified as particularly harmful: excessive salt intake, low consumption of whole grains (such as wholemeal bread and brown rice), and insufficient fruit consumption. However, it's worth noting that the study focused solely on nutritional quality — factors like chemical contamination and the level of food processing were not included, even though they clearly play a role in health outcomes.
We often hear that ultra-processed products are harmful. Why is that?
In Belgium, about 35% of the adult population's daily caloric intake comes from ultra-processed foods, according to the NOVA classification. These are foods that have undergone extensive industrial processing, including chemical, biological, or physical transformations. Such processes alter the food matrix, which is the structural and functional architecture of a food item.
Two foods may have the same nutritional composition on paper but differ in matrix, leading to different effects on health. For example, in dairy products, changes to the matrix caused by processing can affect satiety and nutrient absorption. Additionally, ultra-processed foods often contain ingredients not typically found in traditional cooking, such as additives, colourings, artificial flavours, emulsifiers, hydrogenated oils, and modified proteins. A growing body of research links these ingredients to obesity, type 2 diabetes, and other chronic health conditions.
Could including the NOVA score on product labels positively influence consumer purchasing behaviour?
While information alone doesn't solve everything, it would likely raise public awareness about the degree of food processing and its impact on health. Currently, I believe most people are poorly informed on this issue — especially since the level of processing is not among the five core public dietary recommendations.
If both the NOVA score and the Nutri-Score were made mandatory on food labels, products receiving unfavourable ratings from both systems could face reputational and commercial consequences. That level of transparency could also motivate manufacturers to reformulate their products to improve health profiles.
There is scientific literature exploring how the two labelling systems could be combined. Unfortunately, given the European Commission's decision not to mandate the Nutri-Score, we do not appear to be heading in the right direction.
What solutions do you see for helping consumers make better dietary choices?
We need to implement changes at multiple levels of the food environment. A number of evidence-based interventions are already recognized by local, national, and international authorities. These include restricting marketing of unhealthy foods, tightening regulation of additives, taxing sugar-sweetened beverages, implementing policies that make fresh, minimally processed foods more accessible.
Equally important is providing comprehensive nutritional education from an early age. While these interventions can directly influence eating behaviours, they are not sufficient on their own.
On a broader scale, we need to rethink how food is produced, processed, and distributed. This calls for systemic change and agricultural policies that prioritize quality over quantity.
What role can health professionals play in encouraging this change?
A strong alliance between researchers, health professionals, activists, citizens, and environmental groups can form a meaningful counterbalance to dominant forces in the food system. This coalition has the potential to produce and share independent knowledge, mobilize public opinion, and influence policy change.
However, for such a movement to be truly impactful, it must be supported by a systemic understanding of food issues. That means institutional backing, sustained public funding, and a political will that prioritizes public health and the common good. Sadly, when we look at current debates — such as those around university funding — the direction does not appear promising.
Do you think health professionals' voices carry more weight with public authorities than others?
Yes, I believe health professionals can play a more central role. Their voices carry a high degree of public trust and credibility, which can shape public debate and influence decision-making.
That said, to make a lasting impact, health professionals need to be well-informed about the broader dimensions of food systems, including not only nutrition and patient care but also social, economic, and environmental factors.
Creating the conditions and support systems that enable their active participation in public discourse and advocacy is also crucial. There is still significant progress to be made in this area.
Despite the challenges, are you optimistic about the future of our diets?
I try to remain optimistic — especially as someone at the beginning of my career. Through my research, I'm increasingly aiming to contribute to policy discussions and engage with communities on the ground.
There are promising local initiatives, particularly in Liège, that show how things can move forward. While these efforts currently tend to reach more affluent populations, we're starting to see some projects extend to disadvantaged groups as well. That's an encouraging sign, especially since much remains to be done to reduce social inequalities in nutrition and health.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

time3 hours ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75

Yahoo

time5 hours ago

  • Yahoo

Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75

Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'

Best-ever map of the human genome sheds light on 'jumping genes,' 'junk DNA' and more
Best-ever map of the human genome sheds light on 'jumping genes,' 'junk DNA' and more

Yahoo

time5 hours ago

  • Yahoo

Best-ever map of the human genome sheds light on 'jumping genes,' 'junk DNA' and more

When you buy through links on our articles, Future and its syndication partners may earn a commission. Twenty-two years after the completion of the Human Genome Project, scientists have unveiled the most expansive catalog of human genetic variation ever compiled. Across two new papers published Wednesday (July 23) in the journal Nature, scientists sequenced the DNA of 1,084 people around the world. They leveraged recent technological advancements to analyze long stretches of genetic material from each person, stitched those fragments together and compared the resulting genomes in fine detail. The results deepen our understanding of "structural variants" within the human genome. Rather than affecting a single "letter" in DNA's code, such variations affect large chunks of the code — they may be deleted from or added to the genome, or encompass places where the DNA has been flipped around or moved to a different location. The studies have revealed "hidden" features of the human genome that were previously too technologically challenging to study, said Jan Korbel, the interim head of European Molecular Biology Laboratory (EMBL) Heidelberg, who is a co-author of both new papers. For instance, large portions of the genome contain codes that repeat over and over, and these were thought to be nonfunctional. "Some 20 years ago, we thought about this as 'junk DNA' — we gave it a very bad term," Korbel told Live Science. "There's more and more the realization that these sequences are not junk," and the new work sheds light on these long-maligned DNA sequences. Additionally, all of the data generated in the new studies are open access, so others in the field can now take "the findings, some of the tools we've developed and use them for their purposes to understand the genetic basis of disease," Korbel told Live Science. "I thoroughly believe that the advances that we're publishing in Nature today, a subset of these will also make it into diagnostics." Related: People's racial and ethnic identities don't reflect their genetic ancestry Over 1,000 genomes When the first draft of a "complete" human genome was published in 2003, it was actually missing about 15% of its sequence due to technological limitations of the time. In 2013, scientists managed to close that gap by about half. And finally, in 2022, the first "gapless" human genome was published. In 2023, researchers published the first draft of a human pangenome, which incorporated DNA from 47 people around the world, rather than predominantly being based on one person's DNA. And that same year, researchers published the first Y chromosome that had ever been sequenced from end to end, because the previous "gapless" genome was still missing the male sex chromosome. In the past few years, the field has continued to advance, thanks to new technologies and efforts to expand DNA sampling beyond populations of mostly European descent. Those advancements heralded the two papers published in Nature this week. In the first study, researchers sequenced the DNA of 1,019 people representing 26 populations across five continents. To analyze the DNA, the researchers collected "long reads," each composed of tens of thousands of base pairs; one base pair corresponds with one rung in the spiral ladder of a DNA molecule. "With short reads of around 100 base pairs, it is difficult to distinguish between genomic regions that look alike," explained study co-author Jesus Emiliano Sotelo-Fonseca, a doctoral student at the Centre for Genomic Regulation (CGR) in Barcelona, Spain. That's especially true in repetitive regions of the genome. "With longer reads, of around 20k base pairs, assigning each read to a unique position in the genome gets much easier," he told Live Science in an email. More than half of the new genomic variation uncovered in the study was found in those tricky repetitive regions, including in transposons, also known as jumping genes. Transposons can leap to different locations in the genome, copying and pasting their code. Sometimes, depending on where they land, they can destabilize the genome, introduce harmful mutations and contribute to diseases like cancer. "Our study reveals that some of these transposons can hijack regulatory sequences to boost their activity, contributing to understanding the biological mechanisms behind their mutagenicity," or ability to trigger mutations, study co-author Bernardo Rodríguez-Martín, an independent fellow at CGR and a former postdoc in Korbel's EMBL lab, told Live Science in an email. The jumping genes can essentially hitch a ride with certain regulatory molecules — long noncoding RNAs — and use that trick to make far more copies of themselves than they usually would. "That's a very surprising mechanism to us," Korbel said. Related: Scientists just discovered a new way cells control their genes From 95% to 99% The second study featured far fewer genomes — only 65 in total — but sequenced those genomes more comprehensively than the first study did. The first study captured about 95% of each genome analyzed, while the second study generated 99%-complete genomes. "It might sound like a small difference, but it's huge actually from the perspective of the genome scientist," Korbel said. "To get the last few percentages, it's a major achievement." That leap required different sequencing techniques, as well as new analytical approaches. "This project used cutting-edge software to assemble genomes and identify genetic variation, much of which simply did not exist a few years ago," co-author Charles Lee, a professor at the Jackson Laboratory for Genomic Medicine, told Live Science in an email. The sequencing techniques included one that generated long reads with very few errors and one that generated ultralong reads that were slightly more error-prone. At the expense of analyzing fewer genomes, this approach nonetheless enabled the second study to capture stretches of DNA that were totally missed in the first, Rodríguez-Martín said. Those "hidden" regions included the centromeres, important structures at the centers of chromosomes that are key for cell division. As a cell prepares to split, fibers attach to the centromeres and then pull the chromosome in two. The study found that, in about 7% of centromeres, there are likely two places where these fibers can attach, instead of only one. "Could that mean that those chromosomes are more unstable? Because if the spindle [fiber] attaches to two points, it might get confused," Korbel said. That's a purely speculative idea, he added, but it's one that can now be explored. The next step will be to study the effects of these centromere variations experimentally, Lee agreed. Issues with chromosome splitting can lead to various conditions. For example, "Down syndrome is the result of a mistake of chromosome segregation during cell division in meiosis," when cells split to form sperm and eggs, co-author Dr. Miriam Konkel, an assistant professor at the Clemson University Center for Human Genetics, told Live Science in an email. Like the first study, the second study also provided an unprecedented look at jumping genes, cataloging more than 12,900. Beyond cancer, jumping genes can also trigger various genetic diseases by causing mutations, as well as prompt more subtle changes in how genes are switched on and off, Konkel noted. A better understanding of the diversity of jumping genes can help unpack their function in human health and disease. Looking at both studies, scientists can now compare the newly sequenced genomes to other datasets that include both genome and health data, Korbel noted. This would be the first step toward linking the newfound structural variations to tangible health outcomes and, eventually, to incorporating those insights into medical practice. RELATED STORIES —Largest human family tree ever created retraces the history of our species —More than 150 'made-from-scratch' genes are in the human genome. 2 are totally unique to us. —As little as 1.5% of our genome is 'uniquely human' "Certain clinical studies will not be able to ignore these [sequencing] techniques because they will give them higher sensitivity to identify variation," Korbel said. "You don't want to miss variants." There's still more work to be done to improve the genomic data, as well, Lee added. More DNA could be incorporated from underrepresented populations, and the sequencing techniques and software could be further refined to make the process more efficient and accurate. But in the meantime, the pair of new studies marks a major technological feat. "These advanced tools were developed recently to handle the huge amounts of long-read data we are now using for each genome," Lee said. "A few years back, assembling a complete human chromosome from end to end, especially including centromeres, was virtually unattainable because the software and algorithms were not mature yet." Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store